About Us

We Advance Novel Immunotherapies for Hard-to-Treat Cancers

IMV Inc. is a clinical-stage pharmaceutical company that has the potential to make history by developing a first-in-class effective T cell-targeted immune therapy for cancer. We have built an unprecedented delivery platform (DPX) that generates targeted immune cells directly into the human body, which produces robust, and sustained capabilities to destroy cancer. DPX is the engine that drives our lead drug candidate, maveropepimut-S (DPX-Survivac), which has successfully completed multiple Phase 1/1b trials, generating best-in-class results in advanced recurrent ovarian cancer and Diffuse Large B Cell Lymphoma (DLBCL).

Our Platform Enables a Strong, Targeted, and Sustained Immune Response

Our Platform Enables a Strong, Targeted, and Sustained Immune Response

The unique “no-release” mechanism of action of our DPX™ Platform allows antigen-presenting cells (APCs) to be attracted to the injection site, facilitating antigen presentation to immune cells. All our immunotherapies and vaccines candidates are formulated with the DPX™ platform, giving them the ability to generate, in vivo, a targeted, robust and sustained immune response against cancer cells or viruses.

Partnerships that Pioneer Tomorrow’s Medicine

At IMV, we are accelerating the development of our pipeline and increasing our product candidates through strategic collaborations. We focus on building value for all parties and bringing new options to significant unmet medical needs.

We are actively collaborating with pharmaceutical companies, government agencies, and academic research institutions for research and development.

To contact our Business Development team, please use the form in Contact.

Our Story

It All Began with the Canadian Harp Seal

In the 1980s, a growing seal population threatened the fisheries that supported the economy off Atlantic Canada’s coastal waters. The Canadian Ministry of Fisheries looked to a local expert for help: Warwick Kimmins, Ph.D., the Dean of Sciences at Nova Scotia’s esteemed Dalhousie University. Dr. Kimmins teamed up with fellow biologists, including Robert Brown, Ph.D., to create a contraceptive vaccine that could solve the unbalanced ecosystem.

After several failed attempts, the team turned to an oil-based emulsion to protect the antigens and stimulate the immune system for a longer, stronger time period. Dr. Kimmins, Dr. Brown, and their team achieved contraception in less than half the time. The level of contraception was much higher at close to 90 percent and the strength lasted more than 10 years.

Translating Novel Technology into Commercial Viability

Thinking their process could revolutionize veterinary medicine, Dr. Kimmins and his team converted the technology for other large mammalian species that were overrunning ecosystems. They then made the vaccine delivery technology commercially viable by transferring the method from contraception to infectious diseases. In 2000, Immunovaccine Technologies Inc. (IVT) was born with Dr. Kimmins as the company’s chief executive and Dr. Brown as the first chief scientific officer. IVT proved to be the predecessor to today’s IMV Inc.

Oh, the Humanity!

By 2004, proof-of-concept work began in humans, with an initial focus on infectious diseases. Dr. Kimmins’ emulsion-based delivery formulation became our current DPX™ platform delivery, with one key difference: complete removal of water from the (now completely oil-based) delivery formulation which emerged as the key value driver and scientific differentiator for this technology. In 2009, the team’s focus shifted to human cancers and the Company launched on the Toronto Venture Exchange under the name “Immunovaccine”, with the ticker “IMV.”. has become the name of the company in 2018.

A Novel Class of Immunotherapies

We acquired the survivin antigens from Merck KGaA and reformulated the antigens in our DPX™ delivery platform. We saw in preclinical research that late-stage human cancers could be targeted. This is how our first clinical candidate, DPX-Survivac, emerged. In 2010, we initiated the first human clinical trials of DPX-Survivac. Sadly, Dr. Kimmins passed away before he could see this milestone.

In 2018, the company officially changed its name to IMV Inc. and is listed on the Nasdaq under the ticker symbol IMV. New laboratory facilities were inaugurated in Dartmouth and a corporate office in Quebec City set up us for growth, collaboration and continued innovation.

In 2019, the United States Adopted Names (USAN) Council adopted maveropepimut-S as the chemical name of DPX-Survivac. 

In 2021, maveropepimut-S (DPX-Survivac) is evaluated in phase 2 clinical studies in several cancer indications, including in combination with Merck’s Keytruda®. Our novel targeted Dual T-Cell immunotherapy, DPX-SurMAGE, is also introduced. This new candidate consists in our DPX platform, survivin antigens and MAGE-A9 peptides which are found in various cancers. This dual approach is evaluated in two phase 1 clinical studies. Other DPX-based formulations are evaluated in oncology but also infectious diseases, including a vaccine against RSV (Respiratory Syncytial Virus) and another against the SARS-CoV2 that has caused the COVID-19 pandemic.

We Believe in DPX Unlimited Promise

 “We believed then, as we do now, that the technology held almost unlimited promise,” said Dr. Brown, IMV co-Founder